Elin K. Hansen
Phone: +45 4442 3450
FOR IMMEDIATE RELEASE:
October 29, 2004
Novo Nordisk Expands Production in the United States
to Meet Increasing Demand for its Insulin Products
Clayton, NC -- Novo Nordisk, world leader in diabetes care, has announced plans for 100 million US dollar expansion of its insulin manufacturing plant in Clayton, North Carolina. The company plans to break ground on the new addition within the next few months.
The first phase of the plant expansion, scheduled for completion in 2006, will allow Novo Nordisk to more than double its insulin filling capacity in the US. The second phase will include assembly and packaging facilities for Novo Nordisk's prefilled insulin delivery device FlexPen® as well as administration and storage space, with expected completion in 2007.
"The new facility supports our business strategy in the US by aligning the capacity of our Clayton plant with the increasing demand for Novo Nordisk's insulin products in the US," said Lars Rebien Sørensen, president & CEO of Novo Nordisk. The company has increased its US market share considerably in recent years, driven by the insulin analogues NovoLog® and NovoLog® Mix. Novo Nordisk now holds slightly more than one third of the US insulin market and close to 20% of the analogue market.
Currently, the plant in Clayton handles the formulation, filling and packaging of Novo Nordisk insulin preparations. The site is a high-volume, high speed integrated facility that supplies both the US and other worldwide markets.
A 12 million dollar addition was recently completed.
Novo Nordisk's new expansion will provide around 200 new jobs at the plant in Clayton for a total of 600 when fully operational.
Press photos
Available in the Media - Photo library - Production Section of www.novonordisk.com.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 20,000 full-time employees in 69 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information about Novo Nordisk visit novonordisk.com.
###
RTRP Report | News Releases | Announcements | Accolades
|
